When working with non-alcoholic fatty liver disease, a condition where excess fat accumulates in liver cells of people who drink little or no alcohol. Also known as NAFLD, it often develops alongside metabolic syndrome, a cluster of high blood pressure, elevated blood sugar, excess abdominal fat, and abnormal cholesterol levels. Because the liver is central to processing fats, any disruption in lipid metabolism—like that caused by high triglycerides—can push a healthy liver into steatosis.
One medication that frequently appears in NAFLD discussions is fenofibrate, a PPARα agonist used to lower triglycerides. Lowering triglycerides can reduce the fatty load on liver cells, potentially slowing disease progression. On the flip side, steroids such as methylprednisolone increase glucose production and insulin resistance, which may accelerate fat buildup in the liver. Understanding how each drug tilts the balance helps clinicians and patients make better choices.
Beyond meds, the backbone of NAFLD management is diet and movement. Cutting refined carbs, sugary drinks, and trans fats while boosting fiber and lean protein gives the liver a break from excess calories. Regular aerobic activity improves insulin sensitivity, which directly lowers the liver’s fat storage rate. Even modest weight loss—5 to 10 percent of body weight—can reverse early steatosis and lower inflammation.
Below you’ll find evidence‑based articles that break down these topics in detail: how steroids affect sleep, the impact of fenofibrate on thyroid hormones, and practical tips for monitoring liver health while on common drugs. Use them as a toolbox to personalize your approach to non-alcoholic fatty liver disease and stay ahead of potential complications.
Explore how ursodeoxycholic acid may help treat non‑alcoholic fatty liver disease, covering its mechanism, clinical evidence, dosage, safety, and where it fits in current therapy.